Daily Stock Analysis, RXII, Rxi Pharmaceuticals Corp, priceseries

Rxi Pharmaceuticals Corp. Daily Stock Analysis
Stock Information
Open
0.33
Close
0.33
High
0.33
Low
0.32
Previous Close
0.33
Daily Price Gain
0.00
YTD High
107400.00
YTD High Date
Mar 14, 2013
YTD Low
0.31
YTD Low Date
Nov 15, 2018
YTD Price Change
-38999.67
YTD Gain
-100.00%
52 Week High
107400.00
52 Week High Date
Mar 14, 2013
52 Week Low
0.31
52 Week Low Date
Nov 15, 2018
52 Week Price Change
-38999.67
52 Week Gain
-100.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 26. 2018
1.27
Sep 28. 2018
1.44
2 Trading Days
12.99%
Link
Company Information
Stock Symbol
RXII
Exchange
NasdaqCM
Company URL
http://www.rxipharma.com
Company Phone
(508) 767-3861
CEO
Geert Cauwenbergh
Headquarters
Massachusetts
Business Address
257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA 01752
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001533040
About

RXi Pharmaceuticals Corp. is a biotechnology company. It focuses on discovering, developing and commercializing innovative therapies based on its proprietary, new-generation RNA interference platform. RXi Pharmaceuticals proprietary therapeutic platform is comprised of novel RNAi compounds include rxRNAori and sd-rxRNA. Its clinical product candidate is RXI-109 a self-delivering RNAi compound developed for the reduction of dermal scarring in planned surgeries. RXI-109 is designed to reduce the expression of connective tissue growth factor a critical regulator of several biological pathways involved in scarring and fibrotic diseases. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Description

RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and a Phase I/II clinical trial in retinal scarring. It is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, a formulation of diphenylcyclopropenone, which is in Phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. In addition, the company is developing dermal scarring and wart programs with its sd-rxRNA technology. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.